Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of “Buy” from Brokerages

Shares of Arvinas, Inc. (NASDAQ:ARVN) have received an average recommendation of “Buy” from the thirteen analysts that are currently covering the firm, MarketBeat reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year is $60.00.

A number of analysts have recently commented on ARVN shares. BTIG Research started coverage on shares of Arvinas in a research note on Tuesday, December 10th. They set a “buy” rating and a $69.00 target price for the company. Wedbush reissued an “outperform” rating and set a $57.00 target price on shares of Arvinas in a research note on Tuesday, February 11th. Guggenheim reissued a “buy” rating and set a $57.00 target price on shares of Arvinas in a research note on Wednesday, February 12th. Oppenheimer upped their price objective on shares of Arvinas from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research note on Wednesday, December 11th.

Institutional Trading of Arvinas

Several hedge funds have recently made changes to their positions in ARVN. GF Fund Management CO. LTD. purchased a new stake in shares of Arvinas in the 4th quarter valued at approximately $28,000. nVerses Capital LLC acquired a new position in shares of Arvinas in the 3rd quarter worth approximately $39,000. KBC Group NV lifted its holdings in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after acquiring an additional 440 shares during the last quarter. Finally, Quantbot Technologies LP lifted its holdings in shares of Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after acquiring an additional 2,601 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Stock Performance

Shares of Arvinas stock opened at $18.54 on Friday. The firm has a 50-day simple moving average of $18.55 and a two-hundred day simple moving average of $23.02. The company has a market cap of $1.27 billion, a P/E ratio of -6.69 and a beta of 1.88. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $51.99.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the previous year, the company earned ($2.53) earnings per share. Equities research analysts forecast that Arvinas will post -3.81 EPS for the current year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.